Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · July 27, 2022

Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed AML

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
J. Clin. Oncol 2022 Jun 15;[EPub Ahead of Print], TM Kadia, PK Reville, X Wang, CR Rausch, G Borthakur, N Pemmaraju, NG Daver, CD DiNardo, K Sasaki, GC Issa, M Ohanian, G Montalban-Bravo, NJ Short, N Jain, A Ferrajoli, KN Bhalla, E Jabbour, K Takahashi, R Malla, K Quagliato, R Kanagal-Shamanna, UR Popat, M Andreeff, G Garcia-Manero, MY Konopleva, F Ravandi, HM Kantarjian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading